What Continuous Hormone Tracking Is—and Why It Matters Now
Continuous hormone tracking is the ongoing, real-time monitoring of hormonal patterns through a wearable device that infers endocrine changes from physiological signals instead of drawing blood or collecting urine. Clair Health is bringing this idea to consumers with what it calls the first noninvasive continuous hormone monitor built into a jewelry-inspired wristband. Backed by USD 11.6 million (approx. RM54.4 million) in seed funding from Khosla Ventures, a16z speedrun and others, the startup aims to give hormones the same level of visibility that wearables already give sleep, heart rate and activity. According to Clair, its device focuses on four key hormones—estrogen, progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH)—which shape everything from mood and fertility to recovery and metabolism. For women accustomed to intermittent lab tests or guesswork apps, this marks a shift toward continuous, data-driven women’s health monitoring.
Inside Clair’s Noninvasive Wearable Technology
Clair’s hormone tracking wearable looks like jewelry but functions as a dense sensor platform on the wrist. The band uses 10 biosensors, including biomagnetic sensors, to capture signals such as skin temperature, heart rate variability and electrodermal activity. More than 130 proprietary biomarkers feed Clair’s AI models, which infer where a user is in their hormonal cycle rather than measuring hormones directly. The company reports 94% accuracy in classifying menstrual cycle phases when benchmarked against daily urine samples, and an independent study with the Stanford Gladstone BeeHive program is underway to validate performance. Clair has also trained AI to interpret voice-based biomarkers, claiming it can identify cycle phase after a short conversation. While the initial launch is as a wellness product, Clair plans to seek FDA clearance later, signaling ambitions that go beyond lifestyle tracking into more clinically relevant women’s health monitoring.
Redefining the Menstrual Cycle and Female Physiology
One of Clair’s most attention-grabbing claims is that beta data reveal nine distinct hormonal sub-phases in the menstrual cycle, more than double the four phases women typically learn. For decades, textbook diagrams have simplified cycles into neat blocks, yet real physiology is more fluid and variable. Continuous hormone tracking can surface day-to-day transitions, asymmetries between cycles and atypical patterns that static blood tests miss. This is where noninvasive wearable technology may reshape the map of female biology. Longevity-focused observers see parallels with continuous glucose monitors and biological age clocks: the shift from snapshots to trajectories. If Clair’s nine-phase model is validated in peer-reviewed research, it could change how clinicians interpret symptoms like mood swings, energy dips and sleep changes across the month, and how researchers design studies that finally reflect the true complexity of women’s endocrine rhythms.
From Fertility to Perimenopause: Everyday Uses and Limits
Clair positions its hormone tracking wearable as a daily tool for cycle awareness, fertility timing, performance and menopause transition support. The app is designed to translate continuous hormone patterns into personalized insights on ovulation windows, recovery readiness, possible conditions like PCOS and perimenopausal fluctuations. Early demand is strong: Clair cites a waitlist above 25,000 people, a sold-out first run of 5,000 units months before launch, and more than 100 letters of intent from fertility clinics. For women, the core promise is practical—no repeated blood draws, no urine strips, and data that follow them through changing life stages. At the same time, Clair remains a wellness product without published clinical trials so far. Users and clinicians will need to treat outputs as decision support, not diagnosis, until independent studies confirm accuracy and define how best to act on continuous hormone intelligence.
